Home » Stocks » RARE

Ultragenyx Pharmaceutical Inc. (RARE)

Stock Price: $141.54 USD 5.29 (3.88%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 9.48B
Revenue (ttm) 271.03M
Net Income (ttm) -186.57M
Shares Out 60.85M
EPS (ttm) -3.07
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $141.54
Previous Close $136.25
Change ($) 5.29
Change (%) 3.88%
Day's Open 138.06
Day's Range 134.53 - 142.44
Day's Volume 433,921
52-Week Range 31.99 - 179.65

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

NOVATO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products ...

Benzinga - 1 week ago

Health Canada approves Ultragenyx Pharmaceutical Inc's (NASDAQ: RARE) Dojolvi (triheptanoin) as a source of calories and fatty acids for the treatment of adult and pediatric patients with long...

GlobeNewsWire - 1 week ago

First Approved Treatment for Adult and Pediatric Patients with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) in Canada First Approved Treatment for Adult and Pediatric Patients with Long...

Zacks Investment Research - 2 weeks ago

Ultragenyx (RARE) reports a narrower year-over-year loss and sales beat estimates in the fourth quarter of 2020.

Zacks Investment Research - 2 weeks ago

Ultragenyx (RARE) delivered earnings and revenue surprises of -26.42% and 28.65%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 weeks ago

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 77.16% over the past year to ($0...

GlobeNewsWire - 2 weeks ago

2020 total revenue of $271.0 million and 2020 Crysvita 1 revenue to Ultragenyx of $138.9 million

GlobeNewsWire - 3 weeks ago

NOVATO, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and u...

Zacks Investment Research - 1 month ago

Ultragenyx's (RARE) IND application for UX701 for the treatment of Wilson Disease gets FDA clearance.

GlobeNewsWire - 1 month ago

Clinical trial will utilize a single-protocol Phase 1/2/3 design

Zacks Investment Research - 1 month ago

Ultragenyx (RARE) provides preliminary 2020 Crysvita revenues and 2021 revenue guidance for the same.

GlobeNewsWire - 1 month ago

Durable and Clinically Meaningful Responses Reported from Phase 1/2 Studies of DTX401 for GSDIa and DTX301 for OTC

GlobeNewsWire - 1 month ago

NOVATO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and u...

Zacks Investment Research - 1 month ago

Ultragenyx (RARE), which has a strong pipeline, receives a few approvals for its products in 2020.

Zacks Investment Research - 1 month ago

Some biotech stocks have risen more than 200% this year. Here we discuss five such stocks.

Other stocks mentioned: FATE, MRNA, MRSN, NTLA
InvestorPlace - 1 month ago

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: AMRS, CNSP, CYRN, MREO, NGD, XELA
Seeking Alpha - 2 months ago

The recent acquisition of rare dug heavyweight Alexion Pharmaceuticals signals a willingness of big pharma to enter the field. Typically, big pharma was interested in larger patient population...

Zacks Investment Research - 2 months ago

The biotech sector has been in focus through 2020 as companies like Moderna (MRNA) strive hard to develop a vaccine for COVID-19.

Other stocks mentioned: EDIT, FATE, FOLD, XLRN
Zacks Investment Research - 2 months ago

Ultragenyx (RARE) and Mereo BioPharma ink an agreement for setrusumab, a monoclonal antibody in clinical development for osteogenesis imperfecta.

GlobeNewsWire - 2 months ago

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise

Zacks Investment Research - 2 months ago

Ultragenyx (RARE) gets Orphan Drug Designation from the FDA for UX701 for the treatment of Wilson disease.

GlobeNewsWire - 2 months ago

NOVATO, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products ...

GlobeNewsWire - 2 months ago

Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit

GlobeNewsWire - 3 months ago

NOVATO, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products ...

GlobeNewsWire - 3 months ago

State-of-the-art facility to be located in Bedford, Massachusetts

GlobeNewsWire - 3 months ago

NOVATO, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products ...

GlobeNewsWire - 3 months ago

NOVATO, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products f...

Investors Business Daily - 3 months ago

Stock Market Crumbles; Indexes Dive, More Leaders Break; Monolithic Power, Ultragenyx Strong

Stock market crumbles: Indexes Dive More Leaders Break; Monolithic Power, Ultragenyx strong. Investor's Business Daily has been helping people invest smarter results by providing exclusive sto...

Other stocks mentioned: MPWR
GlobeNewsWire - 3 months ago

NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products f...

Zacks Investment Research - 3 months ago

Ultragenyx (RARE) reports a narrower loss year over year and sales beat estimates in the third quarter of 2020.

GlobeNewsWire - 3 months ago

NOVATO, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products f...

Seeking Alpha - 3 months ago

Ultragenyx Pharmaceutical Inc. (RARE) CEO Emil Kakkis on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Ultragenyx (RARE) delivered earnings and revenue surprises of 8.87% and 47.64%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Investors Business Daily - 4 months ago

Ultragenyx Pharmaceutical posted third-quarter results late Tuesday that beat views on the top and bottom lines after RARE stock hit a nearly five-year high, revenue more than triples. The pos...

Benzinga - 4 months ago

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 42.35% over the past year t...

GlobeNewsWire - 4 months ago

Third quarter 2020 total revenue of $ 81.5 million and Crysvita 1 revenue of $37.3 million

GlobeNewsWire - 4 months ago

Efficacy in multiple functional measures observed in all five patients treated

GlobeNewsWire - 4 months ago

- Collaboration combines Solid's differentiated microdystrophin construct and Ultragenyx's HeL a PCL manufacturing platform for use with AAV8 and variants -

GlobeNewsWire - 4 months ago

NOVATO, Calif. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products...

GlobeNewsWire - 5 months ago

NOVATO, Calif., Sept. 25, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel produc...

GlobeNewsWire - 5 months ago

NOVATO, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel produc...

GlobeNewsWire - 5 months ago

Ms. Dier will start in new role in November 2020 Ms. Dier will start in new role in November 2020

GlobeNewsWire - 5 months ago

NOVATO, Calif., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel produc...

Zacks Investment Research - 5 months ago

Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 6 months ago

Ultragenyx (RARE) reports a narrower-than-expected loss in the second quarter of 2020 and beats sales estimates.

Seeking Alpha - 6 months ago

Ultragenyx Pharmaceutical Inc.'s (RARE) CEO Emil Kakkis on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

Ultragenyx (RARE) delivered earnings and revenue surprises of 47.44% and 53.22%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Two U.S. FDA approvals in second quarter 2020

GlobeNewsWire - 7 months ago

NOVATO, Calif., July 24, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel product...

GlobeNewsWire - 7 months ago

Established UltraCare® Program Provides Ongoing Patient Support Services Established UltraCare® Program Provides Ongoing Patient Support Services

About RARE

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolv... [Read more...]

Industry
Biotechnology
IPO Date
Jan 31, 2014
CEO
Emil Kakkis
Employees
893
Stock Exchange
NASDAQ
Ticker Symbol
RARE
Full Company Profile

Financial Performance

In 2020, RARE's revenue was $271.03 million, an increase of 161.32% compared to the previous year's $103.71 million. Losses were -$186.57 million, -53.67% less than in 2019.

Financial Statements

Analyst Forecasts

According to 15 analysts, the average rating for RARE stock is "Buy." The 12-month stock price forecast is 157.00, which is an increase of 10.92% from the latest price.

Price Target
$157.00
(10.92% upside)
Analyst Consensus: Buy